新型微生物来源的针对不同靶点的抗肿瘤药物研究进展  

Research progress in new anti-tumor drugs on different targets derived from microorganisms

作　　者：陈淑珍[1] 甄永苏[1] CHEN Shu-zhen;ZHEN Yong-su(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050, China)

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《药学学报》2018年第6期833-838,共6页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81621064);中国医学科学院医学与健康科技创新工程经费资助(2016-I2M-2-002)

摘　　要：复杂多样的微生物产生的代谢产物是药物研发的重要资源。利用新的靶点对微生物代谢产物进行筛选,发现了许多针对不同靶点的抗肿瘤药物。作用于各种靶点和信号通路的抗肿瘤抗生素是研究抗肿瘤特殊靶点的重要成员,而抗体偶联药物的"弹头"分子也是包含对肿瘤细胞有极强杀伤作用的抗肿瘤抗生素。本文将对微生物来源、针对不同靶点的抗肿瘤活性物质和高效"弹头"分子进行综述,为研究微生物来源、具有靶向作用的抗肿瘤药物研究提供文献依据。The metabolites produced by complex and diverse microorganisms are important resources for drug research and development. Using new targets to screen microbial metabolites, many anti-cancer drugs acting on different targets are discovered. Anti-tumor antibiotics acting on various targets and signaling pathways are important members in the study of specific targets for anti-tumor, and some anticancer antibiotics with potent antitumor activity are used as ＂warheads＂ of antibody-drug conjugates. Microbial-derived anti-tumor substances acting on different targets with high-efficiency ＂warheads＂ molecules are reviewed to provide a literature basis for research on the anti-cancer drugs for specific targets derived from microorganisms.

关 键 词：抗肿瘤活性物质 靶点 抗体药物偶联物“弹头”分子 

分 类 号：R963[医药卫生—微生物与生化药学]